|
|
Article: A.P. Pharma Reports 2005 Full Year and Fourth Quarter Results; APF530 Phase 3 Clinical Trial Planning at Advanced Stage, Patient Enrollment Expected to Begin in April.
- Article from:
- Business Wire
- Article date:
- March 15, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
REDWOOD CITY, Calif. -- A.P. Pharma, Inc. (NASDAQ NM: APPA), a specialty pharmaceutical company, today reported financial results for the year and three months ended December 31, 2005.
Recent and Financial Highlights
-- APF530 for the prevention of acute and delayed
chemotherapy-induced nausea and vomiting (CINV) in patients
undergoing moderately and highly emetogenic chemotherapy:
-- Held end of Phase 2 meeting with U.S. Food and Drug
Administration (FDA).
-- Submitted Phase 3 pivotal trial protocol to the FDA.
-- Making preparations to initiate Phase 3 clinical trial in
April.
-- Cash, cash equivalents and ...